The global eye flu (conjunctivitis) market offers a wide range of treatment options including antibiotic eye drops, antibiotic ointments, and artificial tears drops that provides protection against irritation and infection to the eyes. The increasing prevalence of eye related disorders like conjunctivitis owing to rising pollution levels, excessive usage of digital devices, and growing geriatric population is driving significant demand for these products globally.
The Global Eye Flu (Conjunctivitis) Market is estimated to be valued at US$ 4.54 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030.
Key players operating in the eye flu (conjunctivitis) market are Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, Alembic Pharmaceuticals, Akorn Pharmaceuticals, Alcon, Pfizer, Valeant Pharmaceuticals, Merck & Co., Similasan Corporation, Sun Pharmaceutical Industries, Prestige Consumer Healthcare, Lupin Pharmaceuticals, Alembic Pharmaceuticals, Aurolab, Intas Pharmaceuticals, Sun Pharma, Cipla. The growing prevalence of eye disorders along with increasing awareness regarding eye care is fueling the demand for eye flu treatment products globally. Major players are focusing on global expansion through mergers, acquisitions, and collaborations to strengthen their market presence.
Market key trends
The increasing pollution levels have emerged as a major driver for rising eye infections globally. According to studies, air pollution exposes eyes to particulate matter daily which has significant impact on ocular health leading to problems like conjunctivitis. The frequent usage of digital devices for long duration without proper screen breaks is resulting in digital eye strain causing temporary blurred vision and eye irritation in many individuals. This trend is encouraging people to adopt preventive eye care products for protection against underlying conditions. Major companies in the industry are focusing on development of advanced formulas with soothing botanical extracts to provide relief from irritation and redness caused due to eye flu.
Threat of new entrants: Low startup costs for eye flu treatment but established brands and regulations pose entry barriers.
Bargaining power of buyers: Individual consumers have low bargaining power but large drug buyers can negotiate lower prices.
Bargaining power of suppliers: Established drug makers are major suppliers with specialized expertise giving them significant influence over prices and supply.
Threat of new substitutes: Limited substitute treatments but alternative generic drugs can replace branded options.
Competitive rivalry: Intense competition between global pharmaceutical giants and generic drug producers drives continuous innovations.
North America currently accounts for the largest share of the global eye flu market value due to advanced healthcare systems and high healthcare spending in the US and Canada.
Asia Pacific region is poised to experience the fastest growth during the forecast period aided by rising incomes, growing medical tourism, increasing geriatric population and progressive regulations in major Asian countries.
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it